Head-To-Head Comparison: Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) vs. Embecta (NASDAQ:EMBC)

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Institutional & Insider Ownership

12.4% of Senseonics Holdings, Inc. Common Stock shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Senseonics Holdings, Inc. Common Stock has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Embecta has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares Senseonics Holdings, Inc. Common Stock and Embecta”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senseonics Holdings, Inc. Common Stock	$35.26 million	11.36	-$69.11 million	($2.23)	-4.30
Embecta	$1.08 billion	0.28	$95.40 million	$1.48	3.56

Embecta has higher revenue and earnings than Senseonics Holdings, Inc. Common Stock. Senseonics Holdings, Inc. Common Stock is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Senseonics Holdings, Inc. Common Stock and Embecta, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senseonics Holdings, Inc. Common Stock	1	1	4	0	2.50
Embecta	2	3	0	0	1.60

Senseonics Holdings, Inc. Common Stock currently has a consensus target price of $17.20, indicating a potential upside of 79.54%. Embecta has a consensus target price of $11.00, indicating a potential upside of 108.53%. Given Embecta’s higher possible upside, analysts clearly believe Embecta is more favorable than Senseonics Holdings, Inc. Common Stock.

Profitability

This table compares Senseonics Holdings, Inc. Common Stock and Embecta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senseonics Holdings, Inc. Common Stock	-225.09%	-165.80%	-80.14%
Embecta	8.59%	-19.25%	10.82%

Summary

Embecta beats Senseonics Holdings, Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.